Twenty-month Monitoring of Humoral Immune Response to BNT162b2 Vaccine: Antibody Kinetics, Breakthrough Infections and Adverse Effects

• DOI: 10.20944/preprints202309.0788.v1
• Publication Date: 2023-09-13T01:19:48Z
• Authors: Jaroslaw Walory; Iza Ksiazek; Michal Karynski; Anna Baraniak
• Keywords: Seroconversion; Booster (rocketry); Booster dose

Background: Vaccination is one of the most effective life-saving medical interventions, and introduction SARS-CoV-2 vaccines was intended to prevent serious implications COVID-19. The objectives study were: i) observe humoral immune response BNT162b2 vaccine infection (mainly breakthrough infections), ii) demonstrate persistence anti-SARS-CoV-2 antibodies over time in relation number received doses course infection, iii) determine adverse effects after primary doses. Methods: To assess response, IgG IgA anti-S1 were quantified by ELISA assays. In total, tests carried out seven times almost two years. Results: We demonstrated strong immunogenicity (compared levels before vaccination, 150- 20-fold increases IgA, respectively) vaccine. Over time, we observed a systematic decline antibody levels, which may have contributed infections. Although they caused seroconversion similar booster, such patients fell more rapidly than re-vaccination. On other hand, individuals who did not receive booster(s) present returned pre-vaccination 20 months. commonly recognized injection site redness swelling. Conclusion: highly preventing severe outcomes COVID-19 should be performed regardless prior infection. Booster significantly enhance and, contrast those obtained remain longer.